SG11201706287PA - Bicyclic heterocycles as fgfr inhibitors - Google Patents

Bicyclic heterocycles as fgfr inhibitors

Info

Publication number
SG11201706287PA
SG11201706287PA SG11201706287PA SG11201706287PA SG11201706287PA SG 11201706287P A SG11201706287P A SG 11201706287PA SG 11201706287P A SG11201706287P A SG 11201706287PA SG 11201706287P A SG11201706287P A SG 11201706287PA SG 11201706287P A SG11201706287P A SG 11201706287PA
Authority
SG
Singapore
Prior art keywords
bicyclic heterocycles
fgfr inhibitors
fgfr
inhibitors
heterocycles
Prior art date
Application number
SG11201706287PA
Inventor
Liang Lu
Bo Shen
Alexander Sokolsky
xiaozhao Wang
Liangxing Wu
Wenqing Yao
Yingda Ye
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55442925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201706287P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of SG11201706287PA publication Critical patent/SG11201706287PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201706287PA 2015-02-20 2016-02-19 Bicyclic heterocycles as fgfr inhibitors SG11201706287PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562118698P 2015-02-20 2015-02-20
US201562170936P 2015-06-04 2015-06-04
PCT/US2016/018787 WO2016134320A1 (en) 2015-02-20 2016-02-19 Bicyclic heterocycles as fgfr inhibitors

Publications (1)

Publication Number Publication Date
SG11201706287PA true SG11201706287PA (en) 2017-09-28

Family

ID=55442925

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201706287PA SG11201706287PA (en) 2015-02-20 2016-02-19 Bicyclic heterocycles as fgfr inhibitors
SG10201913036RA SG10201913036RA (en) 2015-02-20 2016-02-19 Bicyclic heterocycles as fgfr inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913036RA SG10201913036RA (en) 2015-02-20 2016-02-19 Bicyclic heterocycles as fgfr inhibitors

Country Status (23)

Country Link
US (4) US9708318B2 (en)
EP (2) EP3259269B9 (en)
JP (2) JP6689871B2 (en)
KR (1) KR102632018B1 (en)
CN (2) CN113004278B (en)
AU (2) AU2016219822B2 (en)
CA (1) CA2976790C (en)
CL (1) CL2017002123A1 (en)
CO (1) CO2017008795A2 (en)
CR (1) CR20170390A (en)
EA (1) EA038045B1 (en)
EC (1) ECSP17062712A (en)
ES (2) ES2895769T3 (en)
IL (1) IL253691B (en)
MA (1) MA51229A (en)
MX (2) MX373169B (en)
MY (1) MY197720A (en)
PE (1) PE20171514A1 (en)
PH (1) PH12017501481A1 (en)
SG (2) SG11201706287PA (en)
TW (1) TWI712601B (en)
UA (1) UA121669C2 (en)
WO (1) WO2016134320A1 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
ES2704744T3 (en) 2012-06-13 2019-03-19 Incyte Holdings Corp Substituted tricyclic compounds as FGFR inhibitors
SMT202100451T1 (en) 2012-07-11 2021-09-14 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
EA035095B1 (en) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Bicyclic heterocycles as fgfr inhibitors
CA2928042C (en) 2013-10-25 2022-05-10 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MX373169B (en) 2015-02-20 2020-04-24 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
WO2018049233A1 (en) 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
SG11201903911UA (en) 2016-11-02 2019-05-30 Novartis Ag Combinations of fgfr4 inhibitors and bile acid sequestrants
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
WO2019047826A1 (en) 2017-09-05 2019-03-14 博奥阿迪斯生物科技公司 Aromatic derivative, preparation method for same, and medical applications thereof
PE20201170A1 (en) 2017-11-01 2020-10-28 Bristol Myers Squibb Co BRIDGE BICYCLE COMPOUNDS AS MODULATORS OF THE X FARNESOID RECEIVER
JP7168149B2 (en) * 2018-02-08 2022-11-09 ▲ザン▼州片仔▲ファン▼薬業股▲フン▼有限公司 Pyrazin-2(1H)-one compounds as FGFR inhibitors
CR20200590A (en) 2018-05-04 2021-04-26 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
MA52493A (en) 2018-05-04 2021-03-10 Incyte Corp FGFR INHIBITOR SALTS
KR102316234B1 (en) 2018-07-26 2021-10-22 주식회사 종근당 1,3,4-Oxadiazole Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
WO2020056132A1 (en) * 2018-09-13 2020-03-19 University Of Southern California Novel fgfr inhibitors and uses thereof
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
TWI829857B (en) * 2019-01-29 2024-01-21 美商英塞特公司 Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US20200316064A1 (en) * 2019-02-15 2020-10-08 Incyte Corporation Cyclin-dependent kinase 2 biomarkers and uses thereof
WO2020177067A1 (en) 2019-03-05 2020-09-10 Bioardis Llc Aromatic derivatives, preparation methods, and medical uses thereof
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
KR102476818B1 (en) * 2019-05-31 2022-12-13 주식회사 종근당 1,3,4-Oxadiazole Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
AU2020284606B2 (en) 2019-05-31 2023-01-19 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN114174270B (en) * 2019-08-08 2023-06-06 漳州片仔癀药业股份有限公司 A crystal form and B crystal form of pyrazine-2(1H)-ketone compound and preparation method thereof
JP7198387B2 (en) * 2019-08-08 2022-12-28 ▲ザン▼州片仔▲ファン▼薬業股▲フン▼有限公司 C and E crystalline forms of pyrazin-2(1H)-one compounds and methods for their preparation
WO2021023195A1 (en) * 2019-08-08 2021-02-11 漳州片仔癀药业股份有限公司 Crystal form d of pyrazine-2(1h)-ketone compound and preparation method therefor
US11535609B2 (en) 2019-08-08 2022-12-27 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Pyrazine-2(1H)-ketone compound preparation method
TW202115024A (en) 2019-08-14 2021-04-16 美商英塞特公司 Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020364007A1 (en) 2019-10-11 2022-04-28 Incyte Corporation Bicyclic amines as CDK2 inhibitors
TWI891666B (en) 2019-10-14 2025-08-01 美商英塞特公司 Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
BR112022010664A2 (en) 2019-12-04 2022-08-16 Incyte Corp DERIVATIVES OF A FGFR INHIBITOR
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AR125588A1 (en) * 2021-03-04 2023-08-02 Lilly Co Eli FGFR3 INHIBITING COMPOUNDS
TW202304459A (en) 2021-04-12 2023-02-01 美商英塞特公司 Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
WO2023091746A1 (en) 2021-11-22 2023-05-25 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a kras inhibitor
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024112806A1 (en) * 2022-11-21 2024-05-30 Moonwalk Biosciences, Inc. Generation and use of epigenetic maps for drug discovery
CN120530110A (en) * 2022-11-30 2025-08-22 海南先声再明医药股份有限公司 Heterocyclic compound, pharmaceutical composition and use thereof
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc Rmc-6291 for use in the treatment of ras protein-related disease or disorder
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025184010A1 (en) * 2024-03-01 2025-09-04 Merck Sharp & Dohme Llc N-biaryl sulfonamides as modulators of the hippo pathway
WO2025232848A1 (en) * 2024-05-09 2025-11-13 Insilico Medicine Ip Limited Salt-inducible kinases (sik) inhibitors and methods of uses thereof
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026013630A1 (en) * 2024-07-10 2026-01-15 Best Agrolife Limited An improved process for preparation of broflanilide
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (774)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE280853C (en)
US850370A (en) 1906-06-05 1907-04-16 William L Hynes Water-automobile.
DE2156720A1 (en) 1971-11-16 1973-05-24 Bayer Ag Pyrimido(4,5-d) pyrimidines - prepd from polychloroalkylimino acid chloride and 4-amino uracils, are starting materials for plant
US3894021A (en) 1974-01-28 1975-07-08 Squibb & Sons Inc Derivatives of 1,7-dihydro-2H-pyrazolo{8 4{40 ,3{40 :5,6{9 pyrido{8 4,3-D{9 pyrimidine-2,4-(3H)-diones
JPS5120580B2 (en) 1974-06-19 1976-06-25
US4347348A (en) 1978-06-05 1982-08-31 Chernikhov Alexei Y Heat-resistant heterocyclic polymers and methods for producing same
FR2428654A1 (en) 1978-06-13 1980-01-11 Chernikhov Alexei Heat-stable heterocyclic polymer prepn. - by reacting polyfunctional nitrile with polyfunctional isocyanate opt. contg. silicon, halogen, nitrogen, phosphorus and/or boron atoms
CH635828A5 (en) 1978-08-30 1983-04-29 Ciba Geigy Ag N-SUBSTITUTED IMIDES AND BISIMIDS.
CH641470A5 (en) 1978-08-30 1984-02-29 Ciba Geigy Ag SILANES CONTAINING IMID GROUPS.
US4339267A (en) 1980-01-18 1982-07-13 E. I. Du Pont De Nemours And Company Herbicidal sulfonamides
US4402878A (en) 1980-10-22 1983-09-06 Plastics Engineering Company Addition products of di-acetylene-terminated polyimide derivatives with a polyimide having terminal non-conjugated acetylene groups
US4405786A (en) 1980-10-22 1983-09-20 Plastics Engineering Company Addition products of di-acetylene-terminated polyimide derivatives and an dienophile having ethylene groups
US4405520A (en) 1980-10-22 1983-09-20 Plastics Engineering Company Addition products of di-acetylene-terminated polymide derivatives and dienophiles having terminal maleimide grops
US4405519A (en) 1980-10-22 1983-09-20 Plastics Engineering Company Di-Acetylene-terminated polyimide derivatives
US4460773A (en) 1982-02-05 1984-07-17 Lion Corporation 1-Phenyl-1H-pyrazolo [3,4-b]pyrazine derivatives and process for preparing same
JPS59173203A (en) 1983-03-22 1984-10-01 Mitsubishi Metal Corp Shoeless sizing method
DE3432983A1 (en) 1983-09-07 1985-04-18 Lion Corp., Tokio/Tokyo 1,5-disubstituted 1H-pyrazolo[3,4-b]pyrazine derivatives and antitumour agents which contain them
JPS62273979A (en) 1986-05-21 1987-11-28 Lion Corp 1,5-substituted-1H-pyrazolo[3,4-b]pyrazine derivatives and antitumor agents containing the compounds
JPS6310630A (en) 1986-06-23 1988-01-18 Teijin Ltd Production of aromatic polyamide-imide ether
JPS6317882A (en) 1986-07-09 1988-01-25 Lion Corp 5-substituted-1H-pyrazolo[3,4-b]pyrazine derivatives and antitumor agents containing the compounds
US4859672A (en) 1986-10-29 1989-08-22 Rorer Pharmaceutical Corporation Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone
US4874803A (en) 1987-09-21 1989-10-17 Pennwalt Corporation Dianhydride coupled polymer stabilizers
DE3814549A1 (en) 1987-10-30 1989-05-18 Bayer Ag N-SUBSTITUTED DERIVATIVES OF 1-DESOXYNOJIRIMYCIN AND 1-DESOXYMANNONOJIRIMYCIN, METHOD FOR THE PRODUCTION AND USE THEREOF IN MEDICINAL PRODUCTS
JPH029895A (en) 1988-06-28 1990-01-12 Lion Corp Nucleoside analog compound and antitumor agent
DD280853A1 (en) 1989-03-21 1990-07-18 Akad Nauk Sssr BINDER FOR ELECTRODES, PREFERABLY FOR POLYMER ELECTRODES
US5159054A (en) 1989-05-16 1992-10-27 The United States Of America As Represented By The Secretary Of The Navy Synthesis of phthalonitrile resins containing ether and imide linkages
JP2845957B2 (en) 1989-07-17 1999-01-13 三井化学株式会社 Novel diphenols having imide ring and process for producing the same
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
DE3937633A1 (en) 1989-11-11 1991-05-16 Bayer Ag HETEROCYCLIC COMPOUNDS AND THEIR USE AS PIGMENTS AND DYES
DE59009701D1 (en) 1989-12-28 1995-10-26 Hoechst Ag BISCATIONIC ACID AMID AND IMID DERIVATIVES AS CHARGE CONTROL.
US5329046A (en) 1989-12-28 1994-07-12 Hoechst Aktiengesellschaft Biscationic acid amide and imide derivatives and processes for their preparation
JP2883670B2 (en) 1990-03-23 1999-04-19 三井化学株式会社 Novel bisphenol having imide ring and method for producing the same
GB9113137D0 (en) 1990-07-13 1991-08-07 Ici Plc Thioxo heterocycles
KR930702298A (en) 1990-10-03 1993-09-08 알프레드 퍼넷 Diaminobisimide Compound as Main Component of Epoxy Resin
JPH04158084A (en) 1990-10-22 1992-06-01 Fuji Photo Film Co Ltd Recording material
JPH04179576A (en) 1990-11-14 1992-06-26 Fuji Photo Film Co Ltd Recording material
JPH04328121A (en) 1991-04-26 1992-11-17 Sumitomo Bakelite Co Ltd Epoxy resin composition for sealing semiconductor
AU657986B2 (en) 1991-06-14 1995-03-30 Pharmacia & Upjohn Company Imidazo(1,5-a)quinoxalines
DE4119767A1 (en) 1991-06-15 1992-12-17 Dresden Arzneimittel Prepn. of (pyrimid-2-yl-thio- or seleno-) acetic acid derivs. - by reacting the corresp. chloro:alkanoyl-amino cpd. with a rhodanide and water or an alcohol
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
JP3279635B2 (en) 1992-05-18 2002-04-30 鐘淵化学工業株式会社 Hydrosilyl group-containing imide compound
JP3232123B2 (en) 1992-05-20 2001-11-26 鐘淵化学工業株式会社 Curable composition
EP0642510A4 (en) 1992-05-28 1997-04-02 Commw Scient Ind Res Org Bismaleimide compounds.
AU5619094A (en) 1992-12-07 1994-07-04 Commonwealth Scientific And Industrial Research Organisation Bisnadimides
CA2153595A1 (en) 1993-01-11 1994-07-21 Anthony F. Garito Polycyclic aromatic compounds having nonlinear optical properties
WO1994025438A1 (en) 1993-04-28 1994-11-10 The Du Pont Merck Pharmaceutical Company Novel trisubstituted aromatic amines useful for the treatment of cognitive deficits
US5536725A (en) 1993-08-25 1996-07-16 Fmc Corporation Insecticidal substituted-2,4-diamino-5,6,7,8-tetrahydroquinazolines
ES2141916T3 (en) 1993-11-30 2000-04-01 Searle & Co SUBSTITUTED PIRAZOLIL-BENZENOSULPHONAMIDES FOR THE TREATMENT OF INFLAMMATION.
US5480887A (en) 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors
WO1995020965A1 (en) 1994-02-02 1995-08-10 Eli Lilly And Company Hiv protease inhibitors and intermediates
HUT76853A (en) 1994-11-14 1997-12-29 Warner Lambert Co 6-aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation and pharmaceutical compositions containing the same
US7125880B1 (en) 1995-06-06 2006-10-24 Pfizer Inc. Corticotropin releasing factor antagonists
US5783577A (en) 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
JPH09188812A (en) 1996-01-11 1997-07-22 Mitsui Toatsu Chem Inc Crystallization accelerator
JP3531169B2 (en) 1996-06-11 2004-05-24 三菱ウェルファーマ株式会社 Fused heterocyclic compounds and their pharmaceutical uses
US6492520B1 (en) 1996-08-06 2002-12-10 Pfizer Inc Substituted pyrido-or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
JP2000516611A (en) 1996-08-14 2000-12-12 ワーナー―ランバート・コンパニー 2-Phenylbenzimidazole derivatives as MCP-1 antagonists
JP3669783B2 (en) 1996-08-21 2005-07-13 三井化学株式会社 Organic electroluminescence device
US5994364A (en) 1996-09-13 1999-11-30 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
WO1998018781A2 (en) 1996-10-28 1998-05-07 Versicor, Inc. Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents
US6057329A (en) 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
ES2301194T3 (en) 1997-02-05 2008-06-16 Warner-Lambert Company Llc PIRIDO 2,3-D PYRIMIDINS AND 4-AMINOPIRIMIDINAS AS INHIBITORS OF THE CELL PROLIFERATION.
EP0973777A1 (en) 1997-04-11 2000-01-26 Abbott Laboratories Furopyridine, thienopyridine, pyrrolopyridine and related pyrimidine, pyridazine and triazine compounds useful in controlling chemical synaptic transmission
DE69828607T2 (en) 1997-05-28 2006-01-05 Aventis Pharmaceuticals Inc. CHINOLINE AND CHINOXALINE COMPOUNDS WHICH INHIBIT THE GROWTH FACTOR DERIVED FROM BLOOD PLATES AND / OR PDGF AND P56Lck TYROSINE KINASE
GB9716231D0 (en) 1997-07-31 1997-10-08 Amersham Int Ltd Base analogues
CA2300478A1 (en) 1997-08-11 1999-02-18 Cor Therapeutics, Inc. Selective factor xa inhibitors
US6150359A (en) 1997-08-20 2000-11-21 Warner-Lambert Company Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
JPH11171865A (en) 1997-12-04 1999-06-29 Yoshitomi Pharmaceut Ind Ltd Fused heterocyclic compound
CA2316944A1 (en) 1998-02-20 1999-08-26 Mitsuru Shiraishi Aminoguanidinehydrazone derivative, production and use thereof
CA2332239A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
AU763839B2 (en) 1998-05-26 2003-07-31 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
US20040044012A1 (en) 1998-05-26 2004-03-04 Dobrusin Ellen Myra Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
JP2002517486A (en) 1998-06-12 2002-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド inhibitors of p38
ATE459616T1 (en) 1998-08-11 2010-03-15 Novartis Ag ISOCHINOLINE DERIVATIVES WITH ANGIOGENESIS-INHIBITING EFFECT
JP2000123973A (en) 1998-10-09 2000-04-28 Canon Inc Organic light emitting device
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
NZ510760A (en) 1998-10-23 2003-08-29 F Bicyclic nitrogen heterocycles
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
DE19912638A1 (en) 1999-03-20 2000-09-21 Bayer Ag Naphthylcarboxamide substituted sulfonamides
DE19920790A1 (en) 1999-05-06 2000-11-09 Bayer Ag Bis-sulfonamides with anti-HCMV activity
PE20010306A1 (en) 1999-07-02 2001-03-29 Agouron Pharma INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE
JP4041624B2 (en) 1999-07-21 2008-01-30 三井化学株式会社 Organic electroluminescence device
CA2384188C (en) 1999-09-24 2008-06-17 Janssen Pharmaceutica N.V. Antiviral compositions
DE19946289A1 (en) 1999-09-28 2001-03-29 Basf Ag Benzodiazepine derivatives, their production and use
KR100537241B1 (en) 1999-10-21 2005-12-19 에프. 호프만-라 로슈 아게 Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
DE60033307T2 (en) 1999-10-21 2007-07-12 F. Hoffmann-La Roche Ag HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS P38 PROTEIN KINASE INHIBITORS
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
CA2396579A1 (en) 1999-12-29 2001-07-05 Wyeth Tricyclic protein kinase inhibitors
CN1425008A (en) 2000-01-24 2003-06-18 沃尼尔·朗伯公司 3-aminoquinazolin-2, 4-dione antibacterial agents
KR20020070520A (en) 2000-01-27 2002-09-09 워너-램버트 캄파니 Pyridopyrimidinone Derivatives for Treatment of Neurodegenerative Disease
WO2001057038A1 (en) 2000-02-01 2001-08-09 Basf Aktiengesellschaft Heterocyclic compounds and their use as parp inhibitors
DK1257550T3 (en) 2000-02-04 2006-03-27 Portola Pharm Inc The platelet ADP receptor inhibitor
PT1254138E (en) 2000-02-09 2005-09-30 Novartis Ag PYRIDINE DERIVATIVES THAT INHIBIT ANGIOGENESE AND / OR VIRUS TYROSINE KINASE RECEPTOR
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AU2001235804A1 (en) 2000-03-06 2001-09-17 Astrazeneca Ab Therapy
JP2001265031A (en) 2000-03-15 2001-09-28 Fuji Xerox Co Ltd Electrophotographic photoreceptor, process cartridge and electrophotographic device
DE10012549A1 (en) 2000-03-15 2001-09-20 Bayer Ag New heterocyclic-substituted dihydropyrimidine derivatives useful for treatment of viral infections, especially hepatitis B infections
CN1249051C (en) 2000-04-28 2006-04-05 阿卡蒂亚药品公司 Muscarinic agonists
WO2001085722A1 (en) 2000-05-05 2001-11-15 Cor Therapeutics, Inc. Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
EP1296982B1 (en) 2000-06-23 2007-09-19 Bristol-Myers Squibb Pharma Company 1-(heteroaryl-phenyl)-condensed pyrazol derivatives as factor xa inhibitors
ATE273695T1 (en) 2000-06-28 2004-09-15 Smithkline Beecham Plc WET GRINDING
MXPA03001186A (en) 2000-08-07 2004-04-20 Neurogen Corp Heterocyclic compounds as ligands of the gabaa.
EP1309593B1 (en) 2000-08-14 2006-03-15 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
ATE413878T1 (en) 2000-09-06 2008-11-15 Ortho Mcneil Pharm Inc METHOD OF FIGHTING ALLERGIES BY USING SUBSTITUTED PYRAZOLES
GB0025782D0 (en) 2000-10-20 2000-12-06 Pfizer Ltd Use of inhibitors
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
GB0100621D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
WO2002076953A1 (en) 2001-03-21 2002-10-03 Warner-Lambert Company Llc New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US6998408B2 (en) 2001-03-23 2006-02-14 Bristol-Myers Squibb Pharma Company 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
JP2002296731A (en) 2001-03-30 2002-10-09 Fuji Photo Film Co Ltd Heat developable color image recording material
US7074801B1 (en) 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
IL158062A0 (en) 2001-04-30 2004-03-28 Glaxo Group Ltd Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
WO2002094825A1 (en) 2001-05-22 2002-11-28 Banyu Pharmaceutical Co., Ltd. Novel spiropiperidine derivative
US20030114448A1 (en) 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
WO2002102793A2 (en) 2001-06-19 2002-12-27 Warner-Lambert Company Llc Quinazolinediones as antibacterial agents
AU2002315389A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (en) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
US20040235867A1 (en) 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
ATE427935T1 (en) 2001-08-07 2009-04-15 Banyu Pharma Co Ltd SPIRO ISOBENZOFURANES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS
IL160915A0 (en) 2001-09-19 2004-08-31 Aventis Pharma Sa Indolizines inhibiting kinase proteins
ES2269793T3 (en) 2001-10-30 2007-04-01 Novartis Ag DERIVATIVES OF STAUROSPINE AS INHIBITORS OF THE ACTIVITY OF THYROSINE QUINASA RECEPTORA FLT3.
MXPA04004178A (en) 2001-11-01 2004-09-06 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors).
WO2003040131A1 (en) 2001-11-07 2003-05-15 F. Hoffmann-La Roche Ag Aminopyrimidines and pyridines
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
GB0129476D0 (en) 2001-12-10 2002-01-30 Syngenta Participations Ag Organic compounds
ES2251677T3 (en) 2002-01-22 2006-05-01 Warner-Lambert Company Llc 2- (PIRIDIN-2-ILAMINO) -PIRIDO (2,3-D) PIRIMIDIN-7-ONAS.
US7375134B2 (en) 2002-03-05 2008-05-20 Axys Pharmaceuticals, Inc. Cathepsin cysteine protease inhibitors
US6815519B2 (en) 2002-03-22 2004-11-09 Chung-Shan Institute Of Science & Technology Acidic fluorine-containing poly (siloxane amideimide) silica hybrids
EP1492790A1 (en) 2002-04-03 2005-01-05 F. Hoffmann-La Roche Ag Imidazo fused compounds
AU2003234567A1 (en) 2002-05-15 2003-12-02 Janssen Pharmaceutica N.V. N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors
JP4499342B2 (en) 2002-05-16 2010-07-07 株式会社カネカ Method for producing nitrogen-containing organic compound containing SiH group
WO2003099818A1 (en) 2002-05-23 2003-12-04 Chiron Corporation Substituted quinazolinone compounds
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
ES2445208T3 (en) 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. 2,4-Pyrimidinediamine compounds for use in methods to treat or prevent autoimmune diseases
CA2492112A1 (en) 2002-08-06 2004-02-19 F. Hoffmann-La Roche Ag 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
EP1388541A1 (en) 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
US7084270B2 (en) 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
GB0220187D0 (en) 2002-08-30 2002-10-09 Novartis Ag Organic compounds
GB0223349D0 (en) 2002-10-08 2002-11-13 Merck Sharp & Dohme Therapeutic agents
TW200413381A (en) 2002-11-04 2004-08-01 Hoffmann La Roche Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
US7112676B2 (en) 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
AU2003291310A1 (en) 2002-11-06 2004-06-03 Bristol-Myers Squibb Company Fused heterocyclic compounds and use thereof
CL2003002353A1 (en) 2002-11-15 2005-02-04 Vertex Pharma COMPOUNDS DERIVED FROM DIAMINOTRIAZOLS, INHIBITORS D ELA PROTEINA QUINASA; PHARMACEUTICAL COMPOSITION; PREPARATION PROCEDURE; AND ITS USE OF THE COMPOUND IN THE TREATMENT OF DISEASES OF ALLERGIC DISORDERS, PROLIFERATION, AUTOIMMUNES, CONDIC
BR0316375A (en) 2002-11-18 2005-10-04 Hoffmann La Roche Diazinopyrimidines
BR0316680A (en) 2002-11-28 2005-10-18 Schering Ag Chk, pdk and akt inhibitor pyrimidines, their production and use as pharmaceutical agents
EP1567497B1 (en) 2002-12-06 2009-09-23 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
WO2004052862A1 (en) 2002-12-10 2004-06-24 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
CN1753912B (en) 2002-12-23 2011-11-02 惠氏公司 Anti-PD-1 antibodies and uses thereof
JP2004203749A (en) 2002-12-24 2004-07-22 Kanegafuchi Chem Ind Co Ltd Method for producing nitrogen-containing organic compound containing SiH group
EP1590341B1 (en) 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7135469B2 (en) 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
JP2006522756A (en) 2003-04-10 2006-10-05 エフ．ホフマン−ラ　ロシュ　アーゲー Pyrimido compounds
EP1622910A1 (en) 2003-05-05 2006-02-08 F. Hoffmann-La Roche Ag Fused pyrimidine derivatives with crf activity
JP2004346145A (en) 2003-05-21 2004-12-09 Teijin Ltd Imide composition, resin composition comprising the same, and method for producing the same
JP2007501861A (en) 2003-05-23 2007-02-01 カイロン コーポレイション Guanidino-substituted quinazolinone compounds as MC4-R agonists
KR101205257B1 (en) 2003-06-06 2012-11-27 아렉시스 악티에볼라그 Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
EP1637523A4 (en) 2003-06-18 2009-01-07 Ube Industries PROCESS FOR PREPARING A PYRIMIDINE-4-ON COMPOUND
JP2005015395A (en) 2003-06-26 2005-01-20 Japan Science & Technology Agency A novel pyrimidopyrimidine nucleoside and its structural analogs
NZ544472A (en) 2003-07-03 2009-04-30 Myriad Genetics Inc Compounds and therapeutical use thereof
AR045037A1 (en) 2003-07-10 2005-10-12 Aventis Pharma Sa TETRAHIDRO-1H-PIRAZOLO [3,4-C] SUBSTITUTED PYRIDINS, COMPOSITIONS THAT CONTAIN THEM AND ITS USE.
MXPA06001098A (en) * 2003-07-29 2006-04-24 Irm Llc Compounds and compositions as protein kinase inhibitors.
US7390820B2 (en) 2003-08-25 2008-06-24 Amgen Inc. Substituted quinolinone derivatives and methods of use
WO2005028480A2 (en) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
KR20060070572A (en) 2003-09-18 2006-06-23 콘포마 세러퓨틱스 코포레이션 Novel Heterocyclic Compounds as HPS90-Inhibitors
US20070185007A1 (en) 2003-09-19 2007-08-09 Haolun Jin Aza-quinolinol phosphonate integrase inhibitor compounds
AR045944A1 (en) 2003-09-24 2005-11-16 Novartis Ag ISOQUINOLINE DERIVATIVES 1.4-DISPOSED
JP4833069B2 (en) 2003-10-01 2011-12-07 ゼンション・リミテッド Tetrahydro-naphthalene and urea derivatives
AU2004279427B2 (en) 2003-10-08 2008-07-03 Irm Llc Compounds and compositions as protein kinase inhibitors
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
CN1897950A (en) 2003-10-14 2007-01-17 惠氏公司 Fused aryl and heteroaryl derivatives and methods of use
CA2546192C (en) 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
WO2005056524A2 (en) 2003-12-09 2005-06-23 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20080188527A1 (en) 2003-12-23 2008-08-07 Cashman John R Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer
KR100703068B1 (en) 2003-12-30 2007-04-05 에스케이케미칼주식회사 Pyridine derivatives and preparation method thereof, and pharmaceutical composition
EA011277B1 (en) 2004-01-23 2009-02-27 Янссен Фармацевтика Н.В. Quinoline derivatives and use thereof as mycobacterial inhibitors
CA2553969A1 (en) 2004-01-23 2005-08-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP2007529422A (en) 2004-01-29 2007-10-25 エリクシアー ファーマシューティカルズ， インコーポレイテッド Antiviral treatment
GB0402137D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
EP1713806B1 (en) 2004-02-14 2013-05-08 Irm Llc Compounds and compositions as protein kinase inhibitors
BRPI0507852A (en) 2004-02-18 2007-07-10 Warner Lambert Co 2- (pyridin-3-ylamino) -pyrido [2,3-d] pyrimidin-7-ones
KR100843526B1 (en) 2004-02-27 2008-07-03 에프. 호프만-라 로슈 아게 Fused derivatives of pyrazole
AU2005219517A1 (en) 2004-02-27 2005-09-15 F.Hoffmann-La Roche Ag Heteroaryl-fused pyrazolo derivatives
WO2005087765A1 (en) 2004-03-04 2005-09-22 Arena Pharmaceuticals, Inc. Ligands of follicle stimulating hormone receptor and methods of use thereof
WO2005085210A1 (en) 2004-03-10 2005-09-15 Ono Pharmaceutical Co., Ltd. Nitriles and medicinal compositions containing the same as the active ingredient
US7763727B2 (en) 2004-03-29 2010-07-27 Mitsui Chemicals, Inc. Compound and organic electronic device using the same
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
JP2005320288A (en) 2004-05-10 2005-11-17 Mitsui Chemicals Inc Tetracarboxylic acid derivative, electrophotographic photoreceptor given by using the compound, and electrophotographic device
US20050256309A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
MXPA06013805A (en) 2004-05-27 2007-02-02 Pfizer Prod Inc Pyrrolopyrimidine derivatives useful in cancer treatment.
PE20060426A1 (en) 2004-06-02 2006-06-28 Schering Corp TARTARIC ACID DERIVATIVES AS INHIBITORS OF MMPs, ADAMs, TACE AND TNF-alpha
JP4688876B2 (en) 2004-06-10 2011-05-25 アイアールエム・リミテッド・ライアビリティ・カンパニー Compounds and compositions as protein kinase inhibitors
AU2005252110B2 (en) 2004-06-11 2008-09-04 Shionogi & Co., Ltd. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-D] pyrimidine derivatives and related compounds for the treatment of cancer
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
JP2006028027A (en) 2004-07-12 2006-02-02 Mitsui Chemicals Inc Tetracarboxylic acid derivative, electrophotographic photoconductor using the compound and electrohptographic apparatus
KR100853974B1 (en) 2004-08-31 2008-08-25 에프. 호프만-라 로슈 아게 Amide derivatives of 7-amino-3-phenyl dihydropyrimido [4,5-d] pyrimidinone, preparation method thereof, and use as pharmaceutical
BRPI0514738A (en) 2004-08-31 2008-06-24 Hoffmann La Roche 3-phenyl dihydropyrime [4,5-d] pyrimidinones amide derivatives, their manufacture and application as pharmaceutical agents
BRPI0514691A (en) 2004-08-31 2008-06-17 Astrazeneca Ab compound or a pharmaceutically acceptable salt thereof, process for preparing it, pharmaceutical composition, and use of a compound or pharmaceutically acceptable salt thereof
DE102004042667A1 (en) 2004-09-01 2006-03-30 Ewald Dörken Ag Multilayered building wall
US7687113B2 (en) 2004-09-10 2010-03-30 Ube Industries, Inc. Modified polyimide resin and curable resin composition
US20080064680A1 (en) 2004-09-14 2008-03-13 Bamdad Cynthia C Methods for Diagnosis and Treatment of Cancer
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006038112A1 (en) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
FR2876582B1 (en) 2004-10-15 2007-01-05 Centre Nat Rech Scient Cnrse USE OF PYRROLO-PYRAZINE DERIVATIVES FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF MUCOVISCIDOSIS AND DISEASES ASSOCIATED WITH A DEFECT OF ADDRESSING PROTEINS IN CELLS
US20060135553A1 (en) 2004-10-28 2006-06-22 Campbell David A Imidazole derivatives
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
AU2005304952B2 (en) 2004-11-08 2013-04-04 Baxter Healthcare S.A. Nanoparticulate compositions of tubulin inhibitors
JP2008520700A (en) 2004-11-18 2008-06-19 インサイト・コーポレイション Inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods of use thereof
EP1814883A1 (en) 2004-11-22 2007-08-08 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
RU2007123675A (en) 2004-11-24 2008-12-27 Новартис АГ (CH) JAK INHIBITOR COMBINATIONS
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
AU2005316668B2 (en) 2004-12-13 2012-09-06 Millennium Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
US20100152206A1 (en) 2005-01-07 2010-06-17 Ralph Mazitschek Bicyclic Dihydropyrimidines and Uses Thereof
DE102005008310A1 (en) 2005-02-17 2006-08-24 Schering Ag Use of CDKII inhibitors for fertility control
EP1855686A1 (en) 2005-03-01 2007-11-21 Pfizer Limited Use of pde7 inhibitors for the treatment of neuropathic pain
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
CA2610292C (en) 2005-03-30 2015-06-02 Minerva Biotechnologies Corporation Proliferation of muc1 expressing cells
JP2006284843A (en) 2005-03-31 2006-10-19 Mitsui Chemicals Inc Electrophotographic photoreceptor using tetracarboxylic acid derivative and electrophotographing device
US20060223993A1 (en) 2005-04-01 2006-10-05 Connor Daniel M Colorant compounds, intermediates, and compositions
JP2006316054A (en) 2005-04-15 2006-11-24 Tanabe Seiyaku Co Ltd High conductance calcium-sensitive K channel opener
KR100781704B1 (en) 2005-04-20 2007-12-03 에스케이케미칼주식회사 Novel pyridine derivatives, process for preparing thereof and pharmaceutical compositions containing them
MX2007013595A (en) 2005-05-04 2008-01-24 Renovis Inc Fused heterocyclic compounds, and compositions and uses thereof.
RU2494107C2 (en) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Human monoclonal antibodies specific for programmed cell death 1 (pd1) protein and methods of treating cancer with using anti-pd1 antibodies either individually, or in combination with other immunotherapeutic agents
WO2006124731A2 (en) 2005-05-12 2006-11-23 Irm Llc Compounds and compositions as protein kinase inhibitors
KR20080025039A (en) 2005-05-13 2008-03-19 아이알엠 엘엘씨 Compounds and Compositions as Protein Kinase Inhibitors
US20060279115A1 (en) 2005-06-09 2006-12-14 Ash Tisdelle Vehicular head and neck safety system and method
GB0512844D0 (en) 2005-06-23 2005-08-03 Novartis Ag Organic compounds
CN104356236B (en) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 Human monoclonal antibody against programmed death ligand 1 (PD-L1)
EP1915377A1 (en) 2005-07-22 2008-04-30 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
ES2270715B1 (en) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. NEW DERIVATIVES OF PIRAZINA.
JP2009502734A (en) 2005-07-29 2009-01-29 アステラス製薬株式会社 Fused heterocycles as Lck inhibitors
ATE482958T1 (en) 2005-08-09 2010-10-15 Irm Llc COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
MX2008002165A (en) 2005-08-16 2008-04-29 Irm Llc Compounds and compositions as protein kinase inhibitors.
AU2006283935A1 (en) 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag Fused pyrazole as p38 MAP kinase inhibitors
US7678917B2 (en) 2005-09-01 2010-03-16 Hoffman-La Roche Inc. Factor Xa inhibitors
KR20080045266A (en) 2005-09-06 2008-05-22 스미스클라인 비참 코포레이션 Regioselective process for preparing benzimidazole thiopenes
CA2622605A1 (en) 2005-09-15 2007-03-22 Aska Pharmaceutical Co., Ltd. Heterocycle compound, and production process and application thereof
US20070116984A1 (en) 2005-09-21 2007-05-24 Doosan Corporation Spiro-compound for electroluminescent display device and electroluminescent display device comprising the same
US7482360B2 (en) 2005-09-23 2009-01-27 Schering Corporation Fused tetracyclic mGluR1 antagonists as therapeutic agents
DE102005048072A1 (en) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazoles as fungicides
BRPI0617162B8 (en) 2005-10-07 2021-05-25 Exelixis Inc phosphatidylinositol 3-kinase inhibitor compounds pharmaceutical compositions containing them and methods of using them
US8247408B2 (en) 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
WO2007061554A2 (en) 2005-10-21 2007-05-31 Purdue Research Foundation Dosage of 4-aminopyridine derivatives for treatment of central nervous system injuries
TW200800220A (en) 2005-10-26 2008-01-01 Boehringer Ingelheim Int New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007053498A1 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
CN103626742B (en) 2005-11-01 2017-04-26 塔格根公司 Bi-aryl meta-pyrimidine inhibitors of kinases
CA2627839C (en) 2005-11-02 2014-08-19 Bayer Healthcare Ag Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US20070149508A1 (en) 2005-11-02 2007-06-28 Targegen, Inc. Six membered heteroaromatic inhibitors targeting resistant kinase mutations
US8158791B2 (en) 2005-11-10 2012-04-17 Msd K.K. Aza-substituted spiro derivatives
DE602006018057D1 (en) 2005-11-10 2010-12-16 Chemocentryx Inc SUBSTITUTED CHINOLINES AND USE PROCESS
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
EP1953147A1 (en) 2005-11-21 2008-08-06 Japan Tobacco, Inc. Heterocyclic compound and medicinal application thereof
KR101461680B1 (en) 2005-12-02 2014-11-19 바이엘 헬스케어 엘엘씨 Substituted 4-amino-pyrrolotriazine derivatives useful for the treatment of diseases associated with hyper-proliferative disorders and angiogenesis
PE20070855A1 (en) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp DERIVATIVES OF 4-AMINO-PYRROLOTRIAZINE SUBSTITUTE AS KINASE INHIBITORS
CN101365682A (en) 2005-12-08 2009-02-11 千禧药品公司 Bicyclic compounds with kinase inhibitory activity
WO2007066189A2 (en) 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
JP2009520038A (en) 2005-12-19 2009-05-21 ジェネンテック・インコーポレーテッド Pyrimidine kinase inhibitor
BRPI0620408B8 (en) 2005-12-21 2021-05-25 Novartis Ag pyrimidinyl aryl urea derivatives being FGF inhibitors, their uses, and pharmaceutical preparation
WO2007084314A2 (en) 2006-01-12 2007-07-26 Incyte Corporation MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
PE20071025A1 (en) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp TRISUSTITUTED AMINE COMPOUND
US7427625B2 (en) 2006-02-08 2008-09-23 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
WO2007093901A1 (en) 2006-02-17 2007-08-23 Pfizer Limited 3 -deazapurine derivatives as tlr7 modulators
EP2010505B1 (en) 2006-03-28 2012-12-05 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
WO2008117269A2 (en) 2007-03-28 2008-10-02 Atir Holding S.A. Heterotri cyciii c compounds as serotonergic and/or dopaminergic agents and uses thereof
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2647543A1 (en) 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
MX2008012912A (en) 2006-04-06 2008-11-26 Wisconsin Alumni Res Found ANALOGS OF 2-METHYLENE-1A, 25-DIHYDROXI-19,21-DINORVITAMINE D3 AND ITS USES.
JP2009533426A (en) 2006-04-13 2009-09-17 アストラゼネカ・アクチエボラーグ Thioxanthine derivatives and their use as MPO inhibitors
GB0608386D0 (en) 2006-04-27 2006-06-07 Senexis Ltd Compounds
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
AU2007249249A1 (en) 2006-05-11 2007-11-22 Irm Llc Compounds and compositions as protein kinase inhibitors
US20090312321A1 (en) 2006-05-15 2009-12-17 Irm Llc Compositions and methods for fgf receptor kinases inhibitors
US7910108B2 (en) 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
DE102006027156A1 (en) 2006-06-08 2007-12-13 Bayer Schering Pharma Ag New sulfimide compounds are protein kinase inhibitors useful to treat e.g. cancer, Hodgkin's lymphoma, Kaposi's sarcoma, cardiovascular disease, Crohn's disease, endometriosis and hemangioma
CA2656825C (en) 2006-06-22 2013-12-10 Prana Biotechnology Limited Method of treatment and agents useful for same
JP2009541480A (en) 2006-06-30 2009-11-26 アストラゼネカ アクチボラグ Pyrimidine derivatives useful in the treatment of cancer
WO2008005877A2 (en) 2006-06-30 2008-01-10 Board Of Regents, The University Of Texas System Inhibitors of c-kit and uses thereof
JP2009542604A (en) 2006-07-06 2009-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 4-Heterocycloalkylpyrimidines, their preparation and use as pharmaceuticals
US8030487B2 (en) 2006-07-07 2011-10-04 Targegen, Inc. 2-amino—5-substituted pyrimidine inhibitors
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
EP2049481A2 (en) 2006-08-09 2009-04-22 SmithKline Beecham Corporation Novel compounds as antagonists or inverse agonists for opioid receptors
CN101528231A (en) 2006-08-16 2009-09-09 埃克塞利希斯股份有限公司 Use of PI3K and MEK modulators in the treatment of cancer
DE102006041382A1 (en) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl sulfoximides as protein kinase inhibitors
US7956064B2 (en) 2006-09-01 2011-06-07 Cylene Pharmaceuticals, Inc. Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators
US8268809B2 (en) 2006-09-05 2012-09-18 Emory University Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
WO2008033858A2 (en) 2006-09-11 2008-03-20 Cgi Pharmaceuticals, Inc. Kinase inhibitors, and methods of using and identifying kinase inhibitors
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
CA2664095A1 (en) 2006-09-21 2008-03-27 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
ATE493411T1 (en) 2006-09-22 2011-01-15 Glaxo Group Ltd PYRROLOÄ2, 3-BÜPYRIDINE-4-YL-BENZENESULFONAMIDE COMPOUNDS AS IKK2 INHIBITORS
WO2008042639A1 (en) 2006-10-02 2008-04-10 Irm Llc Compounds and compositions as protein kinase inhibitors
PE20081471A1 (en) 2006-10-30 2008-12-31 Glaxo Group Ltd HETEROARYLNITRILE DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS
US7858645B2 (en) 2006-11-01 2010-12-28 Hoffmann-La Roche Inc. Indazole derivatives
WO2008060907A2 (en) 2006-11-10 2008-05-22 Bristol-Myers Squibb Company Pyrrolo-pyridine kinase inhibitors
US7892454B2 (en) 2006-11-17 2011-02-22 Polyera Corporation Acene-based organic semiconductor materials and methods of preparing and using the same
WO2008063609A2 (en) 2006-11-17 2008-05-29 Polyera Corporation Diimide-based semiconductor materials and methods of preparing and using the same
KR20080045536A (en) 2006-11-20 2008-05-23 에스케이케미칼주식회사 Pharmaceutical composition having a hepatitis treatment and prevention or hepatoprotective effect comprising a pyridine compound
ME02372B (en) * 2006-11-22 2016-06-20 Incyte Holdings Corp Imidazotriazines and imidazopyrimidines as kinase inhibitors
CA2672828A1 (en) 2006-12-13 2008-06-26 Schering Corporation Methods of treatment
WO2008071455A1 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
WO2008074068A1 (en) 2006-12-20 2008-06-26 Prana Biotechnology Limited Substituted quinoline derivatives as antiamyloidogeneic agents
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
CA2672518A1 (en) 2006-12-22 2008-07-03 Novartis Ag Organic compounds and their uses
WO2008078091A1 (en) 2006-12-22 2008-07-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
CN101679409B (en) 2006-12-22 2014-11-26 Astex治疗学有限公司 Bicyclic heterocyclic derivative compounds, pharmaceutical compositions thereof and uses thereof
FR2911140B1 (en) 2007-01-05 2009-02-20 Sanofi Aventis Sa NOVEL 2-ANILINO 4-HETEROARYL PYRIMIDES DERIVATIVES, THEIR PREPARATION AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS, AND IN PARTICULAR AS INHIBITORS OF IKK
CN101622253B (en) 2007-01-08 2015-04-29 破立纪元有限公司 Process for the preparation of arene-bis(dicarboximide) based semiconducting materials and related intermediates for their preparation
CN101007778A (en) 2007-01-10 2007-08-01 复旦大学 Chain-prolonged type fluorenyl bimaleimide and its preparation method
SI2114980T1 (en) 2007-01-12 2012-11-30 Biocryst Pharm Inc Antiviral nucleoside analogs
EP2123651A4 (en) 2007-01-12 2011-05-04 Astellas Pharma Inc Condensed pyridine compound
FR2911604B1 (en) 2007-01-19 2009-04-17 Sanofi Aventis Sa N- (HETEROARYL-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
JP5358962B2 (en) 2007-02-06 2013-12-04 住友化学株式会社 Composition and light-emitting device using the composition
JP2008198769A (en) 2007-02-13 2008-08-28 Nippon Steel Chem Co Ltd Organic electroluminescent device
MX2009009492A (en) 2007-03-06 2009-09-15 Novartis Ag Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions.
AU2008223348A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
HRP20151386T1 (en) 2007-03-12 2016-02-26 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
MX2009010060A (en) 2007-03-21 2010-01-20 Epix Pharm Inc Sip receptor modulating compounds and use thereof.
WO2008118454A2 (en) 2007-03-23 2008-10-02 Amgen Inc. Derivatives of quinoline or benzopyrazine and their uses for the treatment of (inter alia) inflammatory diseases, autoimmune diseases or various kinds of cancer
KR20080091948A (en) 2007-04-10 2008-10-15 에스케이케미칼주식회사 Pharmaceutical composition for the prevention and treatment of ischemic diseases containing lactam type pyridine compound
KR20100016477A (en) 2007-04-12 2010-02-12 어드밴스드 테크놀러지 머티리얼즈, 인코포레이티드 Zirconium, hafnuim, titanium, and silicon precursors for ald/cvd
WO2008130584A1 (en) 2007-04-20 2008-10-30 Schering Corporation Pyrimidinone derivatives and methods of use thereof
EP1985612A1 (en) 2007-04-26 2008-10-29 Bayer Schering Pharma Aktiengesellschaft Arymethylen substituted N-Acyl-gamma-aminoalcohols
EP1990342A1 (en) 2007-05-10 2008-11-12 AEterna Zentaris GmbH Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
PE20090288A1 (en) 2007-05-10 2009-04-03 Smithkline Beecham Corp QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
GB2449293A (en) 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
SG185285A1 (en) 2007-06-03 2012-11-29 Univ Vanderbilt Benzamide mglur5 positive allosteric modulators and methods of making and using same
WO2008153852A1 (en) 2007-06-07 2008-12-18 Merck & Co., Inc. Tricyclic anilide heterocyclic cgrp receptor antagonists
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
ES2608940T3 (en) 2007-06-15 2017-04-17 Msd K.K. Bicycloaniline derivative
HRP20131167T1 (en) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
EP2018859A1 (en) 2007-07-26 2009-01-28 Bayer Schering Pharma Aktiengesellschaft Arylmethylene substituted N-acyl-beta-amino alcohols
ES2375425T3 (en) 2007-07-26 2012-02-29 Novartis Ag ORGANIC COMPOUNDS.
EP2020404A1 (en) 2007-08-01 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Cyanomethyl substituted N-Acyl Tryptamines
WO2009021083A1 (en) 2007-08-09 2009-02-12 Smithkline Beecham Corporation Quinoxaline derivatives as pi3 kinase inhibitors
WO2009019518A1 (en) 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
US9493419B2 (en) 2007-08-21 2016-11-15 The Hong Kong Polytechnic University Quinoline derivatives as anti-cancer agents
US7960400B2 (en) 2007-08-27 2011-06-14 Duquesne University Of The Holy Ghost Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
WO2009029625A1 (en) 2007-08-27 2009-03-05 Kalypsys, Inc. 4- [heterocyclyl-methyl] -8-fluoro-quinolin-2-ones useful as nitric oxide synthase inhibitors
US8530480B2 (en) 2007-09-04 2013-09-10 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2009030871A1 (en) 2007-09-07 2009-03-12 Vernalis R & D Ltd Pyrrolopyrimidine derivatives having hsp90 inhibitory activity
TW200920357A (en) 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety
WO2009046141A2 (en) 2007-10-01 2009-04-09 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
US8314094B2 (en) 2007-10-05 2012-11-20 Msd K.K Benzoxazinone derivative
EP2209775A1 (en) 2007-10-09 2010-07-28 UCB Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
WO2009049018A1 (en) 2007-10-10 2009-04-16 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
CN101821243B (en) 2007-10-11 2013-05-08 中国科学院上海药物研究所 A class of pyrimidine-substituted phenylpropionic acid derivatives and their use as PPAR agonists
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
WO2009047993A1 (en) 2007-10-13 2009-04-16 Konica Minolta Holdings, Inc. Organic electroluminescent device, display device and illuminating device
US8129371B2 (en) 2007-10-16 2012-03-06 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors
ATE523508T1 (en) 2007-10-25 2011-09-15 Astrazeneca Ab PYRIDINE AND PYRAZINE DERIVATIVES SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES
RU2007139634A (en) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) NEW THIAZOLE-, TRIAZOLE- OR OXADIAZOLE-CONTAINING TETRACYCLIC COMPOUNDS
WO2009056886A1 (en) 2007-11-01 2009-05-07 Astrazeneca Ab Pyrimidine derivatives and their use as modulators of fgfr activity
BRPI0819453A2 (en) 2007-11-28 2014-10-07 Dana Farber Cancer Inst Inc COMPOUND, METHODS TO TREAT A KINASE ACTIVITY DISORDER, TO TREAT CANCER IN A PATIENT, TO INHIBIT KINASE ACTIVITY AND TO IDENTIFY A COMPOUND THAT MODULATES BCR-ABL KINASE ACTIVITY, PHARMACEUTICAL COMPOSITION, KARMACEUTICAL COMPOSITION
JP2011505407A (en) 2007-12-03 2011-02-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Diaminopyridine for treating diseases characterized by excessive or abnormal cell proliferation
BRPI0821209A2 (en) 2007-12-19 2019-09-24 Amgen Inc compound, pharmaceutical composition, methods of treating cancer, reducing tumor size, treating disorders, and reducing metastasis in a tumor.
US20100331333A1 (en) 2007-12-21 2010-12-30 Wyeth Llc Imidazo [1,2-B] Pyridazine Compounds
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8153827B2 (en) 2007-12-27 2012-04-10 Purdue Research Foundation Reagents for biomolecular labeling, detection and quantification employing Raman spectroscopy
FR2926297B1 (en) 2008-01-10 2013-03-08 Centre Nat Rech Scient INHIBITORY CHEMICAL MOLECULES IN THE SPLICE MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICE ANOMALIES.
EA017818B1 (en) 2008-01-24 2013-03-29 Андрей Александрович ИВАЩЕНКО SUBSTITUTED CYCLOALCANO[e OR d]PYRAZOLO[1,5-a]PYRIMIDINES - ANTAGONISTS OF SEROTONIN 5-HTRECEPTORS, METHODS FOR THE PRODUCTION AND THE USE THEREOF
MX2010007587A (en) 2008-01-24 2010-08-04 Ucb Pharma Sa Compounds comprising a cyclobutoxy group.
KR20100119776A (en) 2008-01-24 2010-11-10 알라 캠, 엘엘씨 2-alkylamino-3-arylsulfonyl-cycloalcano[e or d]pyrazolo[1,5-a]pyrimidines/antagonists of serotonin 5-ht6 receptors, methods for the production and the use thereof
MX2010007768A (en) 2008-01-25 2010-11-09 High Point Pharmaceuticals Llc Tricyclic compounds as modulators of tnf-î± synthesis and as pde4 inhibitors.
ES2494365T3 (en) 2008-01-30 2014-09-15 Genentech, Inc. Pyrazolopyrimidine compounds that inhibit PI3K and methods of use
WO2009099982A1 (en) 2008-02-04 2009-08-13 Osi Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
MX2010008700A (en) 2008-02-22 2010-08-30 Hoffmann La Roche Modulators for amyloid beta.
EA201001329A1 (en) 2008-02-22 2011-04-29 Айрм Ллк COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
JP5451646B2 (en) 2008-02-27 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド Inhibitors of 11β-hydroxysteroid dehydrogenase type 1
WO2009108827A1 (en) 2008-02-29 2009-09-03 Wyeth Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
GB0804701D0 (en) 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
WO2009122180A1 (en) 2008-04-02 2009-10-08 Medical Research Council Pyrimidine derivatives capable of inhibiting one or more kinases
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
US8389533B2 (en) 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
WO2009124755A1 (en) 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Compounds with novel medical uses and method of identifying such compounds
WO2009125808A1 (en) 2008-04-11 2009-10-15 第一三共株式会社 Aminocyclohexyl derivative
WO2009125809A1 (en) 2008-04-11 2009-10-15 第一三共株式会社 Piperidine derivatives
EP2277881A4 (en) 2008-04-18 2011-09-07 Shionogi & Co Heterocyclic compound having inhibitory activity on p13k
NZ588830A (en) 2008-04-22 2012-11-30 Portola Pharm Inc Inhibitors of protein kinases
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
CA2720888A1 (en) 2008-04-29 2009-11-05 Novartis Ag Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods
WO2009132980A1 (en) 2008-04-29 2009-11-05 F. Hoffmann-La Roche Ag Pyrimidinyl pyridone inhibitors of jnk.
AR071523A1 (en) 2008-04-30 2010-06-23 Merck Serono Sa FUSIONATED BICYCLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, THE COMPOSITE TO BE USED AS A MEDICINAL PRODUCT IN THE TREATMENT AND PROFILAXIS OF DISEASES, A PHARMACEUTICAL COMPOSITION AND A SET THAT INCLUDES SEPARATE PACKAGES OF THE COMPOUND AND OF AN INGREDIENT
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
GEP20125502B (en) 2008-05-23 2012-04-25 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
WO2009144205A1 (en) 2008-05-30 2009-12-03 Basf Se Rylene-based semiconductor materials and methods of preparation and use thereof
WO2009150150A1 (en) 2008-06-10 2009-12-17 Basf Se Novel transition metal complex and use thereof in organic light-emitting diodes - iii
ES2430053T3 (en) 2008-06-12 2013-11-18 Merck Sharp & Dohme Corp. Procedure to produce bicycloaniline derivatives
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
MX2010014234A (en) 2008-06-19 2011-03-25 Astrazeneca Ab Pyrazole compounds 436.
US8575337B2 (en) 2008-06-24 2013-11-05 Research Foundation Itsuu Laboratory Oxazolidinone derivative having fused ring
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
NZ602832A (en) 2008-07-14 2014-04-30 Gilead Sciences Inc Fused heterocyclic hdac inhibitor compounds
WO2010007099A1 (en) 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
CA2726460C (en) 2008-07-15 2017-02-21 F. Hoffmann-La Roche Ag Novel phenyl-imidazopyridines and pyridazines
JP2011528368A (en) 2008-07-16 2011-11-17 シェーリング コーポレイション Bicyclic heterocyclic derivatives and their use as GPCR modulators
US8822480B2 (en) 2008-07-16 2014-09-02 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and use thereof as GPR119 modulators
UY31982A (en) 2008-07-16 2010-02-26 Boehringer Ingelheim Int DERIVATIVES OF 1,2-DIHYDROPIRIDIN-3-CARBOXAMIDS N-SUBSTITUTED
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
AU2009279936A1 (en) 2008-08-05 2010-02-11 Banyu Pharmaceutical Co., Ltd. Therapeutic compounds
WO2010015643A1 (en) 2008-08-06 2010-02-11 Novartis Ag New antiviral modified nucleosides
US9284297B2 (en) 2008-08-11 2016-03-15 President And Fellows Of Harvard College Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
UY32049A (en) 2008-08-14 2010-03-26 Takeda Pharmaceutical CMET INHIBITORS
EP2342191B1 (en) 2008-09-10 2013-03-20 Mitsubishi Tanabe Pharma Corporation Aromatic nitrogen-containing 6-membered ring compounds and their use
KR101814408B1 (en) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
TW201016676A (en) 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
WO2010045371A1 (en) 2008-10-15 2010-04-22 Gilead Palo Alto, Inc. Pyrido- and pyrimido (1, 2-a) pyrimidine compounds useful as stearoyl coa desaturase inhibitors
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
UY32203A (en) 2008-10-29 2010-05-31 Astrazeneca Ab AMINO PIRIMIDINAS AND ITS USE IN THERAPY
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
WO2010052448A2 (en) 2008-11-05 2010-05-14 Ucb Pharma S.A. Fused pyrazine derivatives as kinase inhibitors
WO2010059552A1 (en) 2008-11-18 2010-05-27 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
JP5743897B2 (en) 2008-11-20 2015-07-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ Compound
WO2010064621A1 (en) 2008-12-03 2010-06-10 コニカミノルタホールディングス株式会社 Organic electroluminescent element, organic electroluminescent element material, display device, and illuminating device
KR101061599B1 (en) 2008-12-05 2011-09-02 한국과학기술연구원 Novel indazole derivatives that are protein kinase inhibitors for the treatment of abnormal cell growth diseases, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing the same as active ingredients
CA2746220A1 (en) 2008-12-08 2010-07-08 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
US8110265B2 (en) 2008-12-09 2012-02-07 The Coca-Cola Company Pet container and compositions having enhanced mechanical properties and gas barrier properties
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
CA2745959A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
EP2376493B1 (en) 2008-12-12 2016-10-05 Msd K.K. Dihydropyrimidopyrimidine derivative
US8232273B2 (en) 2008-12-19 2012-07-31 Genentech, Inc. Heterocyclic compounds and methods of use
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
US8263610B2 (en) 2008-12-30 2012-09-11 Arqule, Inc. Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds
TWI461410B (en) 2008-12-30 2014-11-21 Arqule Inc Substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
EP2379559B1 (en) 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
CA3121743A1 (en) 2009-01-15 2010-07-22 Incyte Holdings Corporation Processes for preparing jak inhibitors and related intermediate compounds
US8592425B2 (en) 2009-01-16 2013-11-26 Merck Sharp & Dohme Corp. Imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines as mark inhibitors
DE102009007038A1 (en) 2009-02-02 2010-08-05 Merck Patent Gmbh metal complexes
JP2010180147A (en) 2009-02-04 2010-08-19 Mitsubishi Gas Chemical Co Inc Cyanic acid ester compound and cured product thereof
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
TW201035102A (en) 2009-03-04 2010-10-01 Gruenethal Gmbh Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
WO2010103306A1 (en) 2009-03-10 2010-09-16 Astrazeneca Uk Limited Benzimidazole derivatives and their use as antivaral agents
WO2010104047A1 (en) 2009-03-11 2010-09-16 国立大学法人京都大学 Polycyclic aromatic compound
US20120022057A1 (en) 2009-03-18 2012-01-26 Schering Corporation Bicyclic compounds as inhibitors of diacyglycerol acyltransferase
CN103739605B (en) 2009-03-23 2016-08-17 伊莱利利公司 For detecting the developer of neurological disorder
US8288428B2 (en) 2009-03-27 2012-10-16 Abbott Laboratories Compounds as cannabinoid receptor ligands
TW201102391A (en) 2009-03-31 2011-01-16 Biogen Idec Inc Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
JP5629752B2 (en) 2009-04-06 2014-11-26 ユニバーシティ・ヘルス・ネットワークＵｎｉｖｅｒｓｉｔｙ Ｈｅａｌｔｈ Ｎｅｔｗｏｒｋ Kinase inhibitor and method for treating cancer using the same
KR101675607B1 (en) 2009-04-07 2016-11-11 에머리티 파마 아베 Isoxazol-3(2h)-one analogs as therapeutic agents
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
JP5531446B2 (en) 2009-04-20 2014-06-25 コニカミノルタ株式会社 ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, DISPLAY DEVICE AND LIGHTING DEVICE
EP2424368B1 (en) 2009-04-29 2014-12-31 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
ES2347630B1 (en) 2009-04-29 2011-09-08 Universitat Ramon Llull SYNTHESIS AND USES OF 4-CIANOPENTANOATOS AND 4-CIANOPENTENOATS SUBSTITUTED.
US20100280067A1 (en) 2009-04-30 2010-11-04 Pakala Kumara Savithru Sarma Inhibitors of acetyl-coa carboxylase
AR078411A1 (en) 2009-05-07 2011-11-09 Lilly Co Eli IMIDAZOLIL VINYL COMPOUND AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
JP5600891B2 (en) 2009-05-15 2014-10-08 コニカミノルタ株式会社 Organic electroluminescence element, display device and lighting device
JP5604808B2 (en) 2009-05-20 2014-10-15 コニカミノルタ株式会社 Organic electroluminescence element, display device and lighting device
JP5629980B2 (en) 2009-05-22 2014-11-26 コニカミノルタ株式会社 Organic electroluminescence element, display device and lighting device
JP5568889B2 (en) 2009-05-22 2014-08-13 コニカミノルタ株式会社 ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, LIGHTING DEVICE, AND ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL
JP5499519B2 (en) 2009-05-27 2014-05-21 コニカミノルタ株式会社 Organic electroluminescence element, display device and lighting device
WO2010136031A1 (en) 2009-05-27 2010-12-02 Københavns Universitet Fibroblast growth factor receptor-derived peptides binding to ncam
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
JP5600894B2 (en) 2009-06-24 2014-10-08 コニカミノルタ株式会社 White organic electroluminescence element, display device and lighting device
LT2445502T (en) 2009-06-25 2017-09-25 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
EP2450348B1 (en) 2009-06-30 2016-12-14 Zeon Corporation Novel diarylamine compound, and anti-aging agent, polymer composition, crosslinked rubber product and molded article thereof, and method for producing diarylamine compound
JPWO2011007819A1 (en) 2009-07-17 2012-12-27 塩野義製薬株式会社 Pharmaceuticals containing lactam or benzenesulfonamide compounds
WO2011011597A1 (en) 2009-07-24 2011-01-27 Duke University Prochelators useful for inhibiting metal-associated toxicity
FR2948568B1 (en) 2009-07-30 2012-08-24 Sanofi Aventis PHARMACEUTICAL FORMULATION
TWI468402B (en) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 Compounds for the reduction of β-amyloid production
MX2012001504A (en) 2009-08-05 2012-06-01 Versitech Ltd Antiviral compounds and methods of making and using there of cross reference to related applications.
JP2012197231A (en) 2009-08-06 2012-10-18 Oncotherapy Science Ltd Pyridine and pyrimidine derivative having ttk-inhibiting action
PH12012500252A1 (en) 2009-08-07 2015-06-26 Chugai Pharmaceutical Co Ltd Aminopyrazole derivative
WO2011018894A1 (en) 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
PE20121148A1 (en) 2009-08-17 2012-09-07 Intellikine Llc HETEROCYCLIC COMPOUNDS AND USES OF THEM
JP5577650B2 (en) 2009-08-24 2014-08-27 コニカミノルタ株式会社 ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, DISPLAY DEVICE AND LIGHTING DEVICE
KR101184115B1 (en) 2009-08-31 2012-09-18 일동제약주식회사 New peptide deformylase inhibitor compounds and the manufacturing process thereof
PH12012500382A1 (en) 2009-09-03 2012-10-22 Bioenergenix Heterocyclic compounds for the inhibition of pask
CA2772790C (en) 2009-09-04 2017-06-27 Benjamin Bader Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
WO2011031740A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
WO2011032050A2 (en) 2009-09-11 2011-03-17 Trius Therapeutics, Inc. Gyrase inhibitors
EP2483275B1 (en) 2009-10-01 2014-10-15 Merck Sharp & Dohme Corp. HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
US8466155B2 (en) 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
GB0917571D0 (en) 2009-10-07 2009-11-25 Karobio Ab Novel estrogen receptor ligands
EP2308866A1 (en) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazoles and their use as fungicides
FR2951172B1 (en) 2009-10-13 2014-09-26 Pf Medicament PYRAZOLOPYRIDINE DERIVATIVES AS ANTI-CANCER AGENT
EP2491033A4 (en) 2009-10-20 2013-03-13 Eiger Biopharmaceuticals Inc Azaindazoles to treat flaviviridae virus infection
KR20110043270A (en) 2009-10-21 2011-04-27 (주)씨에스엘쏠라 Organic light emitting compound and organic light emitting device having same
US8962652B2 (en) 2009-10-22 2015-02-24 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
MY177695A (en) 2009-10-26 2020-09-23 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
CN102596916B (en) 2009-10-30 2015-06-17 诺瓦提斯公司 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]- N-oxide of pyrimidin-4-yl}-1-methyl-urea
KR20110049217A (en) 2009-11-04 2011-05-12 다우어드밴스드디스플레이머티리얼 유한회사 Novel organic light emitting compound and organic electroluminescent device employing the same
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
NZ599866A (en) 2009-11-06 2014-09-26 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
MX2012005332A (en) 2009-11-13 2012-10-15 Oscotec Inc Kinase inhibitors.
US8673928B2 (en) 2009-11-18 2014-03-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP2013032290A (en) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd Novel fused pyrimidine derivative
US20120232073A1 (en) 2009-11-23 2012-09-13 Santhosh Francis Neelamkavil Fused bicyclic pyrimidine derivatives and methods of use thereof
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
EP2332939A1 (en) 2009-11-26 2011-06-15 Æterna Zentaris GmbH Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
KR20120102724A (en) 2009-12-01 2012-09-18 아보트 러보러터리즈 Novel tricyclic compounds
JP2011116840A (en) 2009-12-02 2011-06-16 Fujifilm Corp Pigment fine particle dispersion, photocurable composition using the same, and color filter
AR079257A1 (en) 2009-12-07 2012-01-04 Novartis Ag CRYSTAL FORMS OF 3- (2,6-DICLORO-3-5-DIMETOXI-PHENYL) -1- {6- [4- (4-ETIL-PIPERAZIN-1-IL) -PENYL-AMINO] -PIRIMIDIN-4- IL} -1-METHYL-UREA AND SALTS OF THE SAME
WO2011075517A1 (en) 2009-12-17 2011-06-23 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
US20120258940A1 (en) 2009-12-18 2012-10-11 Giordano Caponigro Method for treating haematological cancers
AU2010341573B2 (en) 2009-12-22 2016-10-13 Vertex Pharmaceuticals Incorporated Isoindolinone inhibitors of phosphatidylinositol 3-kinase
FR2954317B1 (en) 2009-12-23 2012-01-27 Galderma Res & Dev NOVEL PHENOLIC DERIVATIVES, AND THEIR PHARMACEUTICAL OR COSMETIC USE
FR2954315B1 (en) 2009-12-23 2012-02-24 Galderma Res & Dev NOVEL PHENOLIC DERIVATIVES, AND THEIR PHARMACEUTICAL OR COSMETIC USE
US20110207736A1 (en) 2009-12-23 2011-08-25 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
WO2011090666A2 (en) 2009-12-28 2011-07-28 Afraxis, Inc. Methods for treating autism
WO2011082234A1 (en) 2009-12-29 2011-07-07 Polyera Corporation Thionated aromatic bisimides as organic semiconductors and devices incorporating them
WO2011080755A1 (en) 2009-12-29 2011-07-07 Advinus Therapeutics Private Limited Fused nitrogen heterocyclic compounds, process of preparation and uses thereof
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
JP2013516420A (en) 2009-12-30 2013-05-13 アークル インコーポレイテッド Substituted pyrrolo-aminopyrimidine compounds
WO2011082266A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted heterocyclic compounds
US8329705B2 (en) 2009-12-30 2012-12-11 Arqule, Inc. Substituted triazolo-pyrazine compounds
CN102115026A (en) 2009-12-31 2011-07-06 清华大学 One-dimensional nano-structure, preparation method thereof and method for marking by using one-dimensional nano-structure
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
AR079975A1 (en) 2010-01-06 2012-03-07 British Columbia Cancer Agency THERAPEUTIC AGENTS DERIVED FROM BISPHENOL OR METHODS FOR USE, PHARMACEUTICAL COMPOSITIONS AND USE OF THE SAME
KR101483215B1 (en) 2010-01-29 2015-01-16 한미약품 주식회사 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinases
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
WO2011097717A1 (en) 2010-02-15 2011-08-18 University Of Victoria Innovation And Development Corporation Synthesis of bicyclic compounds and method for their use as therapeutic agents
SA111320200B1 (en) 2010-02-17 2014-02-16 ديبيوفارم اس ايه Bicyclic Compounds and their Uses as Dual C-SRC / JAK Inhibitors
MX2012009561A (en) 2010-02-17 2012-11-23 Amgen Inc Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain.
WO2011102441A1 (en) 2010-02-18 2011-08-25 Ntn株式会社 Thickener, grease, method for producing thickener, method for producing grease, and greased bearing
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
EP2536410B1 (en) 2010-02-18 2015-09-23 Merck Sharp & Dohme Corp. Substituted pyrimidine derivatives and their use in treating viral infections
UY33227A (en) 2010-02-19 2011-09-30 Novartis Ag PIRROLOPIRIMIDINE COMPOUNDS AS INHIBITORS OF THE CDK4 / 6
US9403769B2 (en) 2010-02-22 2016-08-02 Advanced Cancer Therapeutics, Llc Small molecule inhibitors of PFKFB3 and glycolytic flux and their methods of use as anti-cancer therapeutics
US8986858B2 (en) 2010-02-26 2015-03-24 Nippon Steel & Sumikin Chemical Co., Ltd. Organic electroluminescent device
WO2011109237A2 (en) 2010-03-02 2011-09-09 Emory University Uses of noscapine and derivatives in subjects diagnosed with fap
WO2011111880A1 (en) 2010-03-08 2011-09-15 주식회사 메디젠텍 Pharmaceutical composition for treating or preventing diseases caused by the nuclear export of gsk3, including a compound for inhibiting the nuclear export of gsk3
US20110237599A1 (en) 2010-03-10 2011-09-29 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
CN103168039B (en) 2010-03-11 2016-08-03 吉利德康涅狄格公司 imidazopyridine SYK inhibitors
BR112012023021A2 (en) 2010-03-16 2016-05-31 Dana Farber Cancer Inst Inc indazole compounds and their uses
ES2677356T3 (en) 2010-03-24 2018-08-01 Amitech Therapeutics Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
CN102918045A (en) 2010-03-31 2013-02-06 百时美施贵宝公司 Substituted pyrrolotriazines as protein kinase inhibitors
CN102153551B (en) 2010-04-02 2012-04-25 济南海乐医药技术开发有限公司 Indazole/azaindazole-based diarylcarbamide/thiocarbamide-structure antineoplastic drug
JP5724204B2 (en) 2010-04-07 2015-05-27 コニカミノルタ株式会社 Organic electroluminescence element, display device, and lighting device
CA2792278C (en) 2010-04-13 2019-05-14 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses
ES2707625T3 (en) 2010-04-16 2019-04-04 Novartis Ag Organic compound for use in the treatment of liver cancer
JP2013525370A (en) 2010-04-22 2013-06-20 ヤンセン ファーマシューティカ エヌ．ベー． Indazole compounds useful as keto hexokinase inhibitors
AR081331A1 (en) 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
CA2812043A1 (en) 2010-04-23 2011-10-27 Kineta, Inc. Pyrimidinedione anti-viral compounds
CN103025744A (en) 2010-04-30 2013-04-03 百时美施贵宝公司 Aza-bicyclic amine n-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
US8759398B2 (en) 2010-05-03 2014-06-24 Biolink Life Sciences, Inc. Phosphorus binder composition for treatment of hyperphosphatemia
US20130137709A1 (en) 2010-05-05 2013-05-30 Nathanael S. Gray Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith
WO2011141848A1 (en) 2010-05-11 2011-11-17 Pfizer Inc. Morpholine compounds as mineralocorticoid receptor antagonists
JP2013529076A (en) 2010-05-11 2013-07-18 アベオ ファーマシューティカルズ， インコーポレイテッド Anti-FGFR2 antibody
TWI513694B (en) 2010-05-11 2015-12-21 Amgen Inc Pyrimidine compounds that inhibit anaplastic lymphoma kinase
US8961917B2 (en) 2010-05-12 2015-02-24 Spectrum Pharmaceuticals, Inc. Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
CA2799154A1 (en) 2010-05-12 2011-11-17 Abbvie Inc. Indazole inhibitors of kinase
GB201008134D0 (en) 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
WO2011147198A1 (en) 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treatment of proliferative diseases
WO2011147199A1 (en) 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treating viral infections
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
PT2576541T (en) 2010-06-04 2016-07-08 Hoffmann La Roche Aminopyrimidine derivatives as lrrk2 modulators
WO2011155983A1 (en) 2010-06-07 2011-12-15 Bikam Pharmaceuticals Inc. Opsin-binding ligands, compositions and methods of use
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
JP2013532153A (en) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド Bispecific antibodies against TIM-3 and PD-1 for immunotherapy against chronic immune disease
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012005744A1 (en) 2010-06-27 2012-01-12 King Saud University One-time password authentication with infinite nested hash claims
US8933070B2 (en) 2010-07-02 2015-01-13 University Health Network Methods of targeting PTEN mutant diseases and compositions therefor
JP2013530199A (en) 2010-07-06 2013-07-25 ノバルティス アーゲー Cyclic ether compounds useful as kinase inhibitors
FR2962437B1 (en) 2010-07-06 2012-08-17 Sanofi Aventis IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR THERAPEUTIC APPLICATION
FR2962438B1 (en) 2010-07-06 2012-08-17 Sanofi Aventis INDOLIZINE DERIVATIVES, PREPARATION METHODS AND THERAPEUTIC APPLICATION
WO2012003544A1 (en) 2010-07-09 2012-01-12 The Walter And Eliza Hall Institute Of Medical Research Protein kinase inhibitors and methods of treatment
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
WO2012008999A2 (en) 2010-07-14 2012-01-19 Merck Sharp & Dohme Corp. Tricyclic compounds as allosteric modulators of metabotropic glutamate receptors
TW201206946A (en) 2010-07-15 2012-02-16 Bristol Myers Squibb Co Compounds for the reduction of beta-amyloid production
KR20130091331A (en) 2010-07-16 2013-08-16 교와 핫꼬 기린 가부시키가이샤 Nitrogenated aromatic heterocyclic ring derivative
WO2012008564A1 (en) 2010-07-16 2012-01-19 協和発酵キリン株式会社 Nitrogenated aromatic heterocyclic ring derivative
EP2598505B1 (en) 2010-07-28 2015-03-18 Bayer Intellectual Property GmbH Substituted imidazo[1,2-b]pyridazines
EP2413140A1 (en) 2010-07-29 2012-02-01 Sanofi Method for identifying a compound having an antiarrhythmic effect as well as uses relating thereto
EP2806008A1 (en) 2010-07-30 2014-11-26 Rohm And Haas Electronic Materials Korea Ltd. Organic electroluminescent device employing organic light emitting compound as light emitting material
US8906943B2 (en) 2010-08-05 2014-12-09 John R. Cashman Synthetic compounds and methods to decrease nicotine self-administration
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012027239A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRROLO[3,2-e]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
CA2809836C (en) 2010-09-01 2019-01-15 Gilead Connecticut, Inc. Pyridinones/pyrazinones, method of making, and method of use thereof for the treatment of disorders mediated by bruton's tyrosine kinase
BR112013007499A2 (en) 2010-09-01 2016-07-12 Genentech Inc pyridazinones - rearing methods and uses
US9326987B2 (en) 2010-09-08 2016-05-03 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
RS54286B1 (en) 2010-09-08 2016-02-29 Glaxosmithkline Intellectual Property Development Limited POLYMORPHS AND SALTS N- [5- [4- (5 - {[(2R, 6S) -2,6-DIMETHYL-4-MORPHOLINYL] METHYL} -1,3-OXAZOL-2-yl) -1H-INDAZZOL- 6-IL] -2 (methyloxy) -3-pyridinyl] -methanesulfonamide
AR082799A1 (en) 2010-09-08 2013-01-09 Ucb Pharma Sa DERIVATIVES OF QUINOLINE AND QUINOXALINE AS QUINASE INHIBITORS
TWI541243B (en) 2010-09-10 2016-07-11 拜耳知識產權公司 Substituted imidazopyridazines
CN103238117A (en) 2010-09-14 2013-08-07 保土谷化学工业株式会社 Charge control agent and toner using same
CN102399233B (en) 2010-09-15 2014-08-13 山东轩竹医药科技有限公司 Dual PI3K and mTOR inhibitor compounds
CN102399220A (en) 2010-09-15 2012-04-04 黄振华 Tricyclic dual PI3K and mTOR inhibitors
WO2012036233A1 (en) 2010-09-17 2012-03-22 塩野義製薬株式会社 Condensed heterocyclic derivative having melanine-concentrating hormone receptor antagonistic activity
GB201015949D0 (en) 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
JO3062B1 (en) 2010-10-05 2017-03-15 Lilly Co Eli Crystalline (r)-(e)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1h-indazol-3-yl)vinyl)-1h-pyrazol-1-yl)ethanol
EP2629777B1 (en) 2010-10-22 2018-12-19 Merck Sharp & Dohme Corp. Bicyclic diamines as janus kinase inhibitors
KR102051881B1 (en) 2010-10-25 2019-12-04 쥐원 쎄라퓨틱스, 인크. Cdk inhibitors
JP2012092049A (en) 2010-10-27 2012-05-17 Sumitomo Chemical Co Ltd Pest control composition and method for controlling pest
US9868728B2 (en) 2010-10-29 2018-01-16 Emory University Quinazoline derivatives, compositions, and uses related thereto
WO2012061337A1 (en) 2010-11-02 2012-05-10 Exelixis, Inc. Fgfr2 modulators
WO2012062462A1 (en) 2010-11-10 2012-05-18 Grünenthal GmbH Substituted heteroaromatic carboxamide and urea derivatives as vanilloid receptor ligands
CN103201261A (en) 2010-11-10 2013-07-10 埃科特莱茵药品有限公司 Lactam derivatives useful as orexin receptor antagonists
JP2012116825A (en) 2010-11-11 2012-06-21 Ehime Univ Method for producing acene diimide compound
KR101171232B1 (en) 2010-11-15 2012-08-06 단국대학교 산학협력단 Spiro Compound and Organic Light Emitting Device Including the Same
WO2012065297A1 (en) 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
EP2640715A1 (en) 2010-11-17 2013-09-25 Amgen Inc. Quinoline derivatives as pik3 inhibitors
CN103221048A (en) 2010-11-18 2013-07-24 卡斯纳莱拉创新药物私人有限公司 Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
CN103402969A (en) 2010-12-22 2013-11-20 利奥实验室有限公司 3-acyl-ingenols II
RU2572549C2 (en) 2010-12-22 2016-01-20 Лео Лэборетериз Лимитед Ingenol-3-acylates iii and ingenol-3-carbamates
EP2468258A1 (en) 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
MX2013007261A (en) 2010-12-23 2013-11-04 Amgen Inc Heterocyclic compounds and their uses.
JP5691508B2 (en) 2010-12-27 2015-04-01 Jnc株式会社 Diimide compound and inkjet ink and use thereof
KR101466150B1 (en) 2010-12-31 2014-11-27 제일모직 주식회사 Compound for organic photoelectric device and organic photoelectric device including the same
WO2012093731A1 (en) 2011-01-06 2012-07-12 Ｊｘ日鉱日石エネルギー株式会社 Imide compound, method for producing same, thickening agent for grease, and grease composition
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
FR2970967B1 (en) 2011-01-27 2013-02-15 Pf Medicament AZAINDAZOLE OR DIAZAINDAZOLE DERIVATIVES AS A MEDICINAL PRODUCT
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
US9434747B2 (en) 2011-02-18 2016-09-06 Medivation Technologies, Inc. Methods of treating diabetes
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
TWI532742B (en) 2011-02-28 2016-05-11 艾伯維有限公司 Tricyclic inhibitors of kinases
WO2012125812A1 (en) 2011-03-17 2012-09-20 Novartis Ag Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
CN103703000B (en) 2011-03-23 2015-11-25 安姆根有限公司 The fused tricyclic double inhibitor of CDK4/6 and FLT3
ITPD20110091A1 (en) 2011-03-24 2012-09-25 Univ Padova USEFUL INHIBITORS FOR RELATED PATHOLOGIES: PHARMACOFORIC MODELS, IDENTIFIED COMPOUNDS BY THESE MODELS, METHODS FOR THEIR PREPARATION, THEIR FORMULATION AND THEIR THERAPEUTIC USE.
TW201302681A (en) 2011-03-25 2013-01-16 Abbott Lab TRPV1 antagonists
CA2828890A1 (en) 2011-04-07 2012-10-11 Genentech, Inc. Anti-fgfr4 antibodies and methods of use
FR2974088A1 (en) 2011-04-12 2012-10-19 Pf Medicament TRI- AND TETRACYCLIC PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS AS ANTI-CANCER AGENTS
SI2710035T1 (en) 2011-05-16 2017-07-31 F. Hoffmann-La Roche Ag Fgfr1 agonists and methods of use
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
CA2836203A1 (en) 2011-05-17 2012-11-22 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
BR112013029246A2 (en) 2011-05-19 2017-02-14 Novartis Ag 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1h-benzimidazol-2-yl] -1h-quinolin-2-one for use in the treatment of adenoid cystic carcinoma
WO2012163942A1 (en) 2011-06-01 2012-12-06 Bayer Intellectual Property Gmbh Substituted aminoimidazopyridazines
AR086656A1 (en) 2011-06-03 2014-01-15 Millennium Pharm Inc COMBINATION OF MEK INHIBITORS AND SELECTIVE INHIBITORS OF QUINASA AURORA A
EP2719743B1 (en) 2011-06-13 2018-08-01 LG Chem, Ltd. Novel compounds and organic electronic device using same
US9284319B2 (en) 2011-06-22 2016-03-15 Bayer Intellectual Property Gmbh Heterocyclyl aminoimidazopyridazines
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
JP6133291B2 (en) 2011-08-12 2017-05-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Pyrazolo [3,4-c] pyridine compounds and methods of use
AU2012295802B2 (en) 2011-08-12 2017-03-30 Nissan Chemical Industries, Ltd. Tricyclic heterocyclic compounds and JAK inhibitors
JP2013049251A (en) 2011-08-31 2013-03-14 Fujifilm Corp Relief printing plate original plate for laser engraving, and, relief printing plate and method for producing the same
WO2013033981A1 (en) 2011-09-06 2013-03-14 江苏先声药物研究有限公司 2,7-naphthyridine derivative, preparation method therefor and use thereof
EP2755482B1 (en) 2011-09-15 2016-06-01 Merck Sharp & Dohme Corp. Combination of mk-1775 and mk-8776 for treating cancer
US9376435B2 (en) 2011-09-23 2016-06-28 Jawaharlal Nehru Centre For Advanced Scientific Research Chromophores for the detection of volatile organic compounds
WO2013041634A1 (en) 2011-09-23 2013-03-28 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
HK1199028A1 (en) 2011-09-30 2015-06-19 Kineta, Inc. Anti-viral compounds
UA111382C2 (en) 2011-10-10 2016-04-25 Оріон Корпорейшн Protein kinase inhibitors
KR101897044B1 (en) 2011-10-20 2018-10-23 에스에프씨 주식회사 Organic metal compounds and organic light emitting diodes comprising the same
KR20140096035A (en) 2011-10-28 2014-08-04 노파르티스 아게 Method of treating gastrointestinal stromal tumors
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
FR2985258A1 (en) 2011-12-28 2013-07-05 Sanofi Sa FGFS RECEPTOR AGONISTIC DIMERS (FGFRS), PREPARATION METHOD AND THERAPEUTIC USE THEREOF
FR2985257B1 (en) 2011-12-28 2014-02-14 Sanofi Sa FGFS RECEPTOR AGONISTIC DIMERS (FGFRS), PREPARATION METHOD AND THERAPEUTIC USE THEREOF
WO2013109027A1 (en) 2012-01-18 2013-07-25 덕산하이메탈(주) Compound, organic electronic element using same and electronic device thereof
US10026905B2 (en) 2012-01-18 2018-07-17 Duk San Neolux Co., Ltd. Compound, organic electric element using the same, and an electronic device thereof
DK2657233T3 (en) 2012-01-19 2014-09-22 Taiho Pharmaceutical Co Ltd 3,5-disubstituted alkynylbenzene compound and salt thereof
EP2817311B1 (en) 2012-02-23 2016-04-06 Bayer Intellectual Property GmbH Substituted benzothienyl-pyrrolotriazines and uses thereof
JP2013179181A (en) 2012-02-28 2013-09-09 Sumitomo Chemical Co Ltd Organic photoelectric conversion element
KR20140138910A (en) 2012-03-14 2014-12-04 루핀 리미티드 Heterocyclyl compounds
US20150072019A1 (en) 2012-03-30 2015-03-12 Novartis Ag Fgfr inhibitor for use in the treatment of hypophosphatemic disorders
JP5120580B1 (en) 2012-05-14 2013-01-16 Ｊｓｒ株式会社 Liquid crystal alignment agent
CN104684505B (en) 2012-05-20 2017-07-07 戴尔马修墨医学研究内结构和服务有限公司 artificial mitral valve
ES2704744T3 (en) 2012-06-13 2019-03-19 Incyte Holdings Corp Substituted tricyclic compounds as FGFR inhibitors
SMT202100451T1 (en) 2012-07-11 2021-09-14 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
US20150202203A1 (en) 2012-07-11 2015-07-23 Novartis Ag Method of Treating Gastrointestinal Stromal Tumors
WO2014019186A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
KR101985259B1 (en) 2012-08-10 2019-06-03 제이에스알 가부시끼가이샤 Liquid crystal aligning agent and compound
WO2014044846A1 (en) 2012-09-24 2014-03-27 Evotec (Uk) Ltd. 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
WO2014048878A1 (en) 2012-09-26 2014-04-03 Evotec (Uk) Ltd. Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia
WO2014062454A1 (en) 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
KR102000211B1 (en) 2012-10-29 2019-09-30 삼성디스플레이 주식회사 Organometallic compound and organic light emitting diode comprising the same
US20140148548A1 (en) 2012-11-28 2014-05-29 Central Glass Company, Limited Fluorine-Containing Polymerizable Monomer And Polymer Compound Using Same
ME02925B (en) 2012-11-28 2018-04-20 Merck Sharp & Dohme COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
WO2014089913A1 (en) 2012-12-12 2014-06-19 山东亨利医药科技有限责任公司 Bicyclic compound functioning as tyrosine kinase inhibitor
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
WO2014105849A1 (en) 2012-12-28 2014-07-03 Xoma (Us) Llc Antibodies specific for fgfr4 and methods of use
TWI629266B (en) 2012-12-28 2018-07-11 藍印藥品公司 Inhibitors of the fibroblast growth factor receptor
KR102030587B1 (en) 2013-01-09 2019-10-10 에스에프씨주식회사 Asymmetric antracene derivatives having two naphthyl groups and organic light-emitting diode including the same
WO2014113191A1 (en) 2013-01-15 2014-07-24 Xiaohu Zhang Hedgehog pathway signaling inhibitors and therapeutic applications thereof
CN103694236B (en) 2013-01-15 2017-05-31 苏州开拓药业股份有限公司 A kind of pyrimidine scaffold has the antitumoral compounds of activity of hedgehog path antagonist
KR101456626B1 (en) 2013-02-01 2014-11-03 대영이앤비 주식회사 Apparatus for protecting negative pressure of refrigerator
WO2014136972A1 (en) 2013-03-07 2014-09-12 国立大学法人九州大学 Supramolecular complex, light-emitting body, and sensor element for detecting organic compound
WO2014138485A1 (en) 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
EP2968285A4 (en) 2013-03-13 2016-12-21 Flatley Discovery Lab Compounds and methods for the treatment of cystic fibrosis
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
CN105209462A (en) 2013-03-14 2015-12-30 艾伯维德国有限责任两合公司 Novel inhibitor compounds of phosphodiesterase type 10A
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
TWI647220B (en) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 Heteroaryl compound and its use
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
TWI628176B (en) 2013-04-04 2018-07-01 奧利安公司 Protein kinase inhibitors
KR101573611B1 (en) 2013-04-17 2015-12-01 주식회사 엘지화학 Fullerene derivatives, organic solar cell using the same and fabricating method thereof
WO2014170063A1 (en) 2013-04-19 2014-10-23 Covagen Ag Novel bispecific binding molecules with antitumoral activity
EA035095B1 (en) * 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Bicyclic heterocycles as fgfr inhibitors
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
WO2014182829A1 (en) 2013-05-09 2014-11-13 Principia Biopharma Inc. Quinolone derivatives as fibroblast growth factor inhibitors
PL3007694T3 (en) 2013-06-14 2018-12-31 Sanofi Pyrazolopyridine derivatives for use in the treatment of bladder cancer
US9670203B2 (en) 2013-06-28 2017-06-06 Beigene, Ltd. Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors
US9670231B2 (en) 2013-06-28 2017-06-06 Beigene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
WO2015000715A1 (en) 2013-07-02 2015-01-08 Syngenta Participations Ag Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents
EP3019491A4 (en) * 2013-07-09 2016-12-21 Dana Farber Cancer Inst Inc KINASE INHIBITORS FOR THE TREATMENT OF DISEASE
NZ715687A (en) 2013-07-11 2019-04-26 Acea Biosciences Inc Pyrimidine derivatives as kinase inhibitors
AR097455A1 (en) 2013-08-28 2016-03-16 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION CONTAINING PYRIMIDINE COMPOSITE AS AN ACTIVE INGREDIENT
MX378288B (en) 2013-10-18 2025-03-10 Eisai R&D Man Co Ltd FGFR4 PYRIMIDINE INHIBITORS.
CA2928042C (en) 2013-10-25 2022-05-10 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
CN105683188B (en) 2013-10-25 2018-02-09 诺华股份有限公司 The ring pyridinyl derivatives of condensed ring two as FGFR4 inhibitor
FR3012330B1 (en) 2013-10-29 2015-10-23 Oreal BIPHASE COMPOSITION COMPRISING AN ESTER OF FATTY ACID AND SUGAR OR A LIQUID ALKYLPOLYGLUCOSIDE OF HLB <8, AND A C8-C18 BRANCHED ALKANE
WO2015066452A2 (en) 2013-11-01 2015-05-07 Foundation Medicine, Inc. Methods of treating pediatric cancers
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
MA38393B1 (en) 2014-03-13 2018-11-30 Sanofi Sa Heteroaryl Compounds and Related Uses
CN104262330B (en) 2014-08-27 2016-09-14 广东东阳光药业有限公司 A kind of urea substituted biphenyl compounds and combinations thereof thing and purposes
MA39484A (en) 2014-09-19 2016-03-24 Bayer Pharma AG BENZYL SUBSTITUTE INDAZOLES USED AS BUB1 INHIBITORS
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US20160115164A1 (en) 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MX373169B (en) 2015-02-20 2020-04-24 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
EP3259246B1 (en) 2015-02-20 2023-03-22 Oregon Health & Science University Derivatives of sobetirome
CA3254279A1 (en) 2015-06-03 2025-03-18 Triastek, Inc. Dosage forms and use thereof
GB201512369D0 (en) 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
BR112018000834B1 (en) 2015-07-15 2022-06-21 Cabot Corporation Silica-reinforced vulcanizable elastomer composites
HK1257747A1 (en) 2015-07-15 2019-10-25 Protagonist Therapeutics Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
ES2733468T3 (en) 2015-07-15 2019-11-29 Hoffmann La Roche Ethinyl derivatives as modulators of metabotropic glutamate receptors
WO2017019846A1 (en) 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
AU2016341445B2 (en) 2015-10-23 2020-08-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
US20170145025A1 (en) 2015-11-19 2017-05-25 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2916874T3 (en) 2015-12-17 2022-07-06 Incyte Corp N-phenyl-pyridine-2-carboxamide derivatives and their use as modulators of the PD-1/PD-L1 protein/protein interaction
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2906460T3 (en) 2016-05-06 2022-04-18 Incyte Corp Heterocyclic compounds as immunomodulators
ES2905980T3 (en) 2016-05-26 2022-04-12 Incyte Corp Heterocyclic compounds as immunomodulators
BR112018076534A2 (en) 2016-06-20 2019-04-02 Incyte Corporation heterocyclic compounds as immunomodulators
MA45669A (en) 2016-07-14 2019-05-22 Incyte Corp HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS
ES2941716T3 (en) 2016-08-29 2023-05-25 Incyte Corp Heterocyclic compounds as immunomodulators
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US10934304B2 (en) 2016-10-05 2021-03-02 Recurium Ip Holdings, Llc Spirocyclic compounds
KR101755556B1 (en) 2016-11-18 2017-07-07 주식회사 케마스 Pharmaceutical composition for prevention or treatment of brain cancer comprising polymorphic form of tetraarsenic oxide and preparation method thereof
KR101834366B1 (en) 2016-11-21 2018-03-05 주식회사 케마스 Pharmaceutical composition for prevention or treatment of breast cancer comprising polymorphic form of tetraarsenic oxide and preparation method thereof
KR101844049B1 (en) 2016-12-05 2018-03-30 주식회사 케마스 Pharmaceutical composition for prevention or treatment of liver cancer comprising polymorphic form of tetraarsenic oxide
KR101844050B1 (en) 2016-12-09 2018-05-14 주식회사 케마스 Pharmaceutical composition for prevention or treatment of cancer comprising polymorphic form of tetraarsenic oxide
ES2899402T3 (en) 2016-12-22 2022-03-11 Incyte Corp Pyridine derivatives as immunomodulators
AU2017382870B2 (en) 2016-12-22 2022-03-24 Incyte Corporation Benzooxazole derivatives as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
ES2874756T3 (en) 2016-12-22 2021-11-05 Incyte Corp Triazolo [1,5-A] pyridine derivatives as immunomodulators
EP3558990B1 (en) 2016-12-22 2022-08-10 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
EP3672973A4 (en) 2017-08-22 2021-05-26 JS Innopharm (Shanghai) Ltd. Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
SG11202004925QA (en) 2017-12-02 2020-06-29 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
CR20200520A (en) 2018-03-30 2021-03-09 Incyte Corp Heterocyclic compounds as immunomodulators
CR20200590A (en) 2018-05-04 2021-04-26 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
MA52493A (en) 2018-05-04 2021-03-10 Incyte Corp FGFR INHIBITOR SALTS
WO2019217821A1 (en) 2018-05-11 2019-11-14 Incyte Corporation Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
CA3108714A1 (en) 2018-08-14 2020-02-20 Osteoqc Inc. Pyrrolo - dipyridine compounds
IL281212B2 (en) 2018-09-07 2023-12-01 Merck Patent Gmbh The history of 5-morpholine-4-yl-pyrazolo[[4,3-Bpyridine and their use
WO2020131627A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
EP3898615A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors

Also Published As

Publication number Publication date
US20160244449A1 (en) 2016-08-25
CN107438607A (en) 2017-12-05
US20170290839A1 (en) 2017-10-12
US11173162B2 (en) 2021-11-16
ECSP17062712A (en) 2017-11-30
US10251892B2 (en) 2019-04-09
MX2020004108A (en) 2022-01-03
TWI712601B (en) 2020-12-11
JP2018511573A (en) 2018-04-26
EP3617205A1 (en) 2020-03-04
EP3259269A1 (en) 2017-12-27
JP2020121994A (en) 2020-08-13
CN113004278B (en) 2023-07-21
IL253691B (en) 2020-11-30
ES2751669T9 (en) 2020-05-21
IL253691A0 (en) 2017-09-28
BR112017017418A8 (en) 2023-01-24
BR112017017418A2 (en) 2018-04-10
HK1246794A1 (en) 2018-09-14
CL2017002123A1 (en) 2018-03-16
PH12017501481B1 (en) 2018-02-05
NZ773116A (en) 2024-05-31
JP6689871B2 (en) 2020-04-28
ES2895769T3 (en) 2022-02-22
PH12017501481A1 (en) 2018-02-05
MX373169B (en) 2020-04-24
UA121669C2 (en) 2020-07-10
MY197720A (en) 2023-07-10
MX388991B (en) 2025-03-20
MA51229A (en) 2021-03-24
PE20171514A1 (en) 2017-10-20
EP3617205B1 (en) 2021-08-04
AU2016219822B2 (en) 2020-07-09
CN113004278A (en) 2021-06-22
CA2976790C (en) 2024-02-27
KR102632018B1 (en) 2024-02-02
WO2016134320A1 (en) 2016-08-25
AU2020250211A1 (en) 2020-11-05
EA038045B1 (en) 2021-06-28
EP3259269B9 (en) 2020-03-04
ES2751669T3 (en) 2020-04-01
NZ734586A (en) 2024-05-31
US9708318B2 (en) 2017-07-18
EP3259269B1 (en) 2019-09-04
CO2017008795A2 (en) 2018-01-16
TW201639838A (en) 2016-11-16
MX2017010673A (en) 2018-03-21
CN107438607B (en) 2021-02-05
SG10201913036RA (en) 2020-02-27
US20200306256A1 (en) 2020-10-01
CA2976790A1 (en) 2016-08-25
AU2020250211B2 (en) 2022-09-29
CR20170390A (en) 2017-10-23
AU2016219822A1 (en) 2017-08-31
KR20170127467A (en) 2017-11-21
US10632126B2 (en) 2020-04-28
US20190269693A1 (en) 2019-09-05
EA201791866A1 (en) 2017-12-29

Similar Documents

Publication Publication Date Title
IL253691B (en) Bicyclic heterocycles as fgfr inhibitors
IL253869A0 (en) Bicyclic heterocycles as fgfr4 inhibitors
SG10201708520YA (en) Bicyclic heterocycles as fgfr inhibitors
IL256581A (en) Substituted aza compounds as irak-4 inhibitors
IL259794A (en) Bicyclic inhibitors of pad4
IL246140A0 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
ZA201608847B (en) Beta-lactamase inhibitors
ZA201801032B (en) Bicyclic compounds as atx inhibitors
HUE059324T2 (en) Heterocyclic compounds as pi3k-gamma inhibitors
SG11201605486WA (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
IL255570A (en) Bicyclic compounds as atx inhibitors
IL251778B (en) New pyrazolopyrimidine derivatives as nik inhibitors
IL255357A0 (en) Bicyclic compounds
ZA201701210B (en) Substituted bicyclic compounds